Sandra Van Wetering

Title: Sandra Van Wetering: Innovator in Cancer Treatment

Introduction

Sandra Van Wetering is a prominent inventor based in Leidschendam, Netherlands. She has made significant contributions to the field of medical sciences, particularly in the development of therapeutic cancer vaccines. With a total of 3 patents to her name, her work focuses on innovative methods for cancer treatment.

Latest Patents

One of her latest patents involves therapeutic cancer vaccines derived from a novel dendritic cell line. This invention provides means and methods for the treatment of cancer by utilizing cells and cell lines that can be developed into fully functional dendritic cells. These cells endogenously express cancer-specific antigens, making them particularly suited for treating various types of cancer. Specifically, the invention relates to a precursor cell line for dendritic cells called DC-One, which was deposited at the DSMZ under accession number DSMZ ACC3189 on November 15, 2012.

Career Highlights

Sandra is currently associated with Dcprime B.V., where she continues her research and development efforts in cancer immunotherapy. Her work has been instrumental in advancing the understanding and application of dendritic cell technology in clinical settings.

Collaborations

She collaborates with notable colleagues, including Adriana Maria Kruisbeek and Tanja Denise De Gruijl, who contribute to her research initiatives and enhance the impact of her inventions.

Conclusion

Sandra Van Wetering's innovative work in the field of cancer treatment exemplifies the potential of dendritic cell technology in medical science. Her contributions are paving the way for new therapeutic approaches that could significantly improve patient outcomes.